Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial

Next Previous
Search
Trial Profile

A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already on interferon-beta therapy: a phase 2a trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexarotene (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms CCMR One

    • Most Recent Events

    • 01 Sep 2021 Additional exclusion criteria applied as per amendment recommended by the trial steering committee during the trial in those with considerable cardiovascular disease or lymphopenia in view of adverse events observed in early trial participants, as per results published in the Lancet Neurology.
    • 01 Sep 2021 Results published in the Lancet Neurology
    • 01 Apr 2016 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top